Madrigal Pharmaceuticals, Inc. (MDGL)
571.33
+18.86
(+3.41%)
USD |
NASDAQ |
Dec 11, 16:00
565.01
-6.32
(-1.11%)
After-Hours: 20:00
Madrigal Pharmaceuticals Research and Development Expense (TTM): 296.43M for Sept. 30, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Amgen, Inc. | 6.828B |
| Alnylam Pharmaceuticals, Inc. | 1.248B |
| Amicus Therapeutics, Inc. | 142.29M |
| Insmed, Inc. | 695.91M |
| Ionis Pharmaceuticals, Inc. | 879.75M |